Hubbell Randolph W 4
4 · ALPHA HEALTHCARE ACQUISITION CORP III · Filed Jul 18, 2023
Insider Transaction Report
Form 4
Hubbell Randolph W
DirectorPresident and CEO
Transactions
- Award
Stock Option (right to buy)
2023-07-14+480,110→ 480,110 totalExercise: $2.11Exp: 2031-09-23→ Common Stock (480,110 underlying) - Award
Stock Option (right to buy)
2023-07-14+217,175→ 217,175 totalExercise: $1.79Exp: 2027-06-20→ Common Stock (217,175 underlying) - Award
Stock Option (right to buy)
2023-07-14+37,642→ 37,642 totalExercise: $2.27Exp: 2029-07-19→ Common Stock (37,642 underlying)
Footnotes (4)
- [F1]Options are fully vested and exercisable.
- [F2]Options to purchase 37,642 shares of common stock of Legacy Carmell (as defined below) granted on July 19, 2019, which vest as follows: 25% vested on July 19, 2020, July 19, 2021 and July 19, 2022. The remaining 25% will vest and become exercisable on July 19, 2023.
- [F3]Options to purchase 480,110 shares of common stock of Legacy Carmell granted on September 23, 2021, which vest as follows: 25% vested on September 23, 2022 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date.
- [F4]On July 14, 2023, Alpha Healthcare Acquisition Corp. III ("ALPA") consummated a business combination (the "Business Combination") by and among ALPA, Candy Merger Sub, Inc., a Delaware Corporation ("Merger Sub") and Carmell Regen Med Corporation, a Delaware corporation ("Legacy Carmell"), ALPA changed its name to "Carmell Therapeutics Corporation" and Merger Sub merged with and into Legacy Carmell. As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation.